Health
Major Asthma Breakthrough: Monthly Injection Safely Reduces Oral Steroid Dependence
N
Next Headline
3 min read
Nov 28, 2025
Featured image for this article
A study in The Lancet confirms that a new monthly injection allows severe asthma patients to safely reduce or stop reliance on oral steroids, mitigating significant long-term side effects.
London, November 29, 2025: A landmark study published in the prestigious medical journal *The Lancet* has offered new hope for patients suffering from severe asthma. The research validates the effectiveness of the monoclonal antibody drug, **tezepelumab** (marketed as Tezspire), when administered as a monthly injection.
The findings demonstrate that the treatment allows patients with severe, oral steroid-dependent asthma to safely reduce or completely eliminate their reliance on daily oral steroids. This is a critical development, as long-term steroid use carries severe side effects, including osteoporosis, diabetes, and immune suppression.
Share this article:
No related articles found